Omepren-D Capsule SR is a combination pharmaceutical formulation containing Domperidone 30 mg and Omeprazole 20 mg, designed for the management of gastrointestinal disorders associated with acid reflux and delayed gastric emptying. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating. Omeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing effective relief from acid-related conditions including gastroesophageal reflux disease (GERD), peptic ulcers, and erosive esophagitis. The sustained-release formulation ensures prolonged therapeutic plasma concentrations, enhancing efficacy and patient compliance through reduced dosing frequency. Omepren-D is indicated for symptomatic treatment of acid reflux accompanied by delayed gastric emptying, improving both motility and acid suppression simultaneously. It should be used under medical supervision, with caution advised in patients with hepatic impairment or known hypersensitivity to either component. Common side effects may include dry mouth, headache, and abdominal discomfort. This combination therapy offers a comprehensive approach to managing upper gastrointestinal motility disorders and acid-related symptoms, optimizing clinical outcomes in affected patients.